Recent searches
Search options
Administered by:
“#RSV sends about half a million children to emergency departments in the U.S. every year; somewhere between 58,000 and 80,000 of those children end up being hospitalized. The #CDC estimates that between 100 and 300 children die from RSV in any given year.
In a Phase 3 clinical trial, the Pfizer #vaccine was shown to reduce the risk of severe #LowerRespiratoryTract disease caused by RSV by 82% at three months after birth and 69% at six months.” https://scicomm.xyz/@HelenBranswell/110930337156889596
@auscandoc Yes, this can be a great first stup! But I doubt this will be a magic bullet. The trial showed non-sign (less good) efficacy in infants <3 months, this vulnerable group (needing lots of in-hospital care in my experience) needs something that works better.
@stefanjohansson Yes. Helen mentioned some of these caveats in her article. I’m also wary of the non significant trend towards premature delivery. We need to see if, in a rollout into a larger population, this become significant.
As well as the possible dampening effect on other vaccines. 